Peer-influenced content. Sources you trust. No registration required. This is HCN.

Features:
CME JOBS OUTBREAKS PEER-TO-PEER QUIZZES & QUESTIONS MEDTECH

The New England Journal of MedicineSotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer

In this single-group, phase 1-2 trial, sotorasib (LUMAKRAS, Amgen) demonstrated antitumor effect in patients with KRAS p.G12C-mutated advanced pancreatic cancer who had undergone prior therapy and had an acceptable safety profile.

Was this Essential useful?

More Essentials From

ACP Internist
ASH Clinical News
Annals of Internal Medicine
British Medical Journal
Cleveland Clinic Journal of Medicine
Clinical Advances in Hematology & Oncology
GoodRx Health
Healthgrades for Professionals
JAMA Network
Journal of Clinical Oncology
KevinMD.com
MedPage Today
Medical Professionals Reference (MPR)
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form